

Name: Michael Ladomery

Group (University, Country): Dr Michael Ladomery, Faculty of Health and Applied Sciences, University of the West of England, Coldharbour Lane, Bristol BS16 1QY, U.K.

E-mail address: Michael.Ladomery@uwe.ac.uk

General research subject: Disrupted alternative splicing in cancer, RNA biology; specific projects, targeting splice factor kinases SRPK1 and CLK1; functions of oncogenic splice isoforms of the ERG oncogene; prostate cancer

Group website: www.ladomerylab.org

Publications (last five years):

1. Adamo P, Porazinski S, Rajatileka S, Jumbe S, Hagen R, Cheung M-K, Wilson I, Ladomery M (2017). "The oncogenic transcription factor ERG represses the transcription of the tumour suppressor gene PTEN in prostate cancer cells". *Onc Lett* OL-8815-E151357.
2. Hannah Hopewell, Kieran G. Floyd, Daniel Burnell, John T. Hancock, Joel Allainguillaume, Michael R. Ladomery, and Ian D. Wilson (2017). "Residual ground-water levels of the neonicotinoid thiacloprid perturb chemo-sensing of *Caenorhabditis elegans*". *Ecotoxicology*, accepted ref.: ECTX-D-16-00274R2.
3. Claire M. Perks, H. A. Zielinska, Jing Wang, Caroline Jarrett, A. Frankow, Michael R. Ladomery, Amit Bahl, Anthony Rhodes, Jon Oxley and Jeff M. P. Holly (2016). "Insulin receptor isoform variations in prostate cancer cells". *Frontiers in Endocrinology*, 7:132.
4. Jolly P, Estrela P, Ladomery M (2016). "Oligonucleotide-based systems: DNA, microRNAs, DNA/RNA aptamers". *Essays Biochem* 60, pp.27-35.
5. Ladomery M, Sommerville J (2015). "The Scd6 protein xRAPB has properties different from RAP55 in selecting mRNA for early translation or intracellular distribution in *Xenopus oocytes*". *BBA Gene Regulatory Mechanisms* 1849, pp. 1363-1373.
6. Maryam A Hamdollah Zadeh, Elianna M Amin, Coralie Hoareau-Aveilla, Enric Domingo, Kirsty E Symonds, Xi Ye, Katherine J Heesom Andrew Salmon, Olivia D'Silva Kai B Betteridge Ann C Williams, David J Kerr, Andrew HJ Salmon, Sebastian Oltean, Rachel S Midgley, Michael R. Ladomery, Steven J Harper, Alexander HR Varey, David O Bates (2015) "Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, and hence angiogenesis, growth and resistance." *Molecular Oncology* 9, pp. 167-178.
7. Adamo, P, Ladomery, M. (2015). "The oncogene ERG: a key player in prostate cancer". Accepted, *Oncogene*, ref. *ONC_ONC2015109*
8. Williams E, Pead S, Whiteman M, Wood ME, Wilson ID, Ladomery MR, Teklic T, Lisjak M, Hancock JT (2015). Detection of thiol modifications by hydrogen sulfide. *Methods Enzymol* 555, pp. 233-251.
9. Sebastian Oltean, Athina Mavrou, Karen Brakspear, Maryam Hamdollah Zadeh, Gopinath Damodaran, Jon Oxley, David Gillatt, Michael Ladomery, Steve Harper, Dave Bates, and Roya Babaei-Jadidi (2015). "SRPK1 inhibition and modulation of VEGF alternative splicing as a potential therapeutic strategy in prostate cancer". *Oncogene* 34, pp. 4311-4319.
10. Rachel M. Hagen, Patricia Adamo, Saima Karamat, Jon Oxley, Jonathan J Aning, David Gillatt, Raj Persad, Michael R. Ladomery*, Anthony Rhodes* (2014) "Quantitative analysis of ERG expression and its splice isoforms in formalin fixed paraffin embedded prostate cancer samples: Association with seminal vesicle invasion and biochemical recurrence". *Am J Clin Pathol* 142, pp. 533-40.

11. Ciuzan O, Wilson I, Pamfil D, Hancock J, Ladomery M. (2014) "The evolutionarily conserved multifunctional class IV glycine-rich RNA binding proteins play key roles in stress adaptation". *Physiologia Plantarum*. Epub ahead of print.
12. Williams E, Pead S, Whiteman M, Wood ME, Wilson ID, Ladomery MR, Teklic T, Lisjak M, Hancock JT (2014) "Detection of thiol modifications by hydrogen sulphide". *Methods in Enzymology*, in press.
13. Hagen, RM, Rhodes, A, Ladomery, MR (2013). "Conjugated linoleate reduces prostate cancer viability whereas the effects of oleate and stearate are cell line-dependent. *Anticancer Research*, 33: pp. 4395-4400.
14. Ladomery MR (2013). Aberrant alternative splicing is another hallmark of cancer. *Int J Cell Biol* 2013:463786, Epub Sep 2013.
15. Sette C, Ladomery MR, Ghigna C (2013). Alternative splicing: role in cancer development and progression. *Int J Cell Biol* 2013:421606.
16. Ignea C, Dorobantu CM, Mintoff CP, Branza-Nichita N, Ladomery MR, Kefalas P, Chedea VS (2013) "Modulation of the antioxidant/pro-oxidant balance, cytotoxicity and antiviral actions of grape seed extracts" *Food Chem*. 141: pp. 3967-3976.
17. Hagen RM, Rhodes A, Oxley J, Ladomery MR (2013). "A MMLV reverse transcriptase with reduced RNaseH activity allows greater sensitivity of gene expression detection in formalin fixed and paraffin embedded prostate cancer samples". *Exp & Mol Pathol* 95, pp 98-104.
18. Ciuzan, O, Ladomery, MR, Wilson, I, Hancock, J, Pamfil, D (2013). "The Arabidopsis thaliana glycine-rich RNA binding proteins atGRP7 and atGRP2 are involved in early development". *ProEnvironment* 6, pp. 72-76.
19. Braicu, C, Ladomery, MR, Chedea, V, Irimie, A, Berindan-Neagoe, I, (2013) "The relationship between the structure and biological actions of green tea catechins". *Food Chem*. 141, pp 3282-3289.
20. Rachel M. Hagen, Veronica S. Chedea, Christopher P. Mintoff, Elizabeth Bowler, H. Ruth Morse & Michael R. Ladomery (2013). "Epigallocatechin-3-gallate promotes apoptosis and expression of the caspase 9a splice variant in PC3 prostate cancer cells". *Int. J. Oncol.* 43, pp.194-200.
21. R.M. Hagen, M.R. Ladomery (2012). "Role of splice variants in the metastatic progression of prostate cancer". *Biochem. Soc. Trans.* 40, pp 870-874.
22. Oltean S, Gammons M, Hulse R, Hamdollah-Zadeh M, Mavrou A, Donaldson L, Salmon AH, Harper SJ, Ladomery MR, Bates DO (2012). "SRPK1 inhibition in vivo: modulation of VEGF splicing and potential treatment for multiple diseases". *Biochem. Soc. Trans.* 40, pp 831-835.
23. Elianna M Amin, Sebastian Oltean, Jing Hua, Melissa Gammons, Man-Kim Cheung, Lan Ni, Maryam Hamdollah-Zadeh, Satoru Kase, Emma S Rennel, Gavin I Welsh, Kirsty E Symonds, Dawid G Nowak, Moin A Saleem, Masatoshi Hagiwara, Brigitte Pokora-Royer, Valérie A Schumacher, Steven J Harper, David R Hinton, David O Bates, Michael R Ladomery. (2011). "WT1 mutants reveal SRPK1 to be a novel downstream angiogenesis target by altering VEGF splicing." *Cancer Cell* 20, pp. 768-780.